ClinicalTrials.gg
CompletedNCT07040826Updated Jun 27, 2025

Lifitegrast Eye Drops in Healthy Subjects:Phase I Study

A Phase 1 interventional study of Xiidra and Lifitegrast in Dry Eye Syndromes, sponsored by Qilu Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-27.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 6 months after the study started (first participant enrolled Dec 2022, registered Jun 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing lifitegrast in Dry Eye Syndromes — 2 open to participants now, 2 under way, none of them phase 3. lifitegrast · Dry Eye Syndromes.

Enrollment
16th of 22
24 · median 38
Started
2022
with 1 other
Phase 1
Only one
of the 22
Registered
18th of 22
by date
Lead sponsor
1 of 22
Qilu Pharmaceutical Co., Ltd.

Among the 22 studies testing lifitegrast in Dry Eye Syndromes, this one is the 16th largest by enrollment, is one of 2 that started in 2022, is the only one in phase 1, and was the 18th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

2 of the 22 studies testing lifitegrast in Dry Eye Syndromes are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About lifitegrast

lifitegrast: first FDA approval 2016 (XIIDRA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing lifitegrast in Dry Eye Syndromes, or all of them as a file.
02

Study summary

This is a single-center, randomized, double-blind, single-dose, two-period crossover Phase I clinical trial designed to:

  • Compare the pharmacokinetic (PK) profiles of Lifitegrast Ophthalmic Solution and Xiidra® in plasma and tears following single-dose administration in healthy subjects.
  • Evaluate the safety and tolerability of Lifitegrast Ophthalmic Solution in healthy subjects.

A total of 24 healthy subjects will be randomized into two treatment sequences (Group A: T/R; Group B: R/T). The study duration per subject will be approximately 36 days, including:

  • Screening Period (Day -21 to Day -1)
  • Treatment Periods (Day 1, followed by a 7-day washout period, then Day 8 or early termination)
  • Safety Follow-up (Day 15, 7 days after the last dose).

On Day 1 of Cycle 1, one study eye will be selected and designated for all subsequent tear PK sampling. Treatment assignments:

  • Group A: Lifitegrast (T) on Day 1, then Xiidra® (R) on Day 8.
  • Group B: Xiidra® (R) on Day 1, then Lifitegrast (T) on Day 8. Each subject will receive one drop of the assigned medication (either Lifitegrast or Xiidra®) in each eye from the same single-dose container. Blood and tear samples will be collected per protocol for PK analysis, including parameters such as Cmax, AUC0-∞, AUC0-t, Tmax, T1/2, λz, and AUC_%Extrap. The PK profiles between the two treatments will be compared to evaluate bioequivalence and assess the safety of Lifitegrast Ophthalmic Solution.
03

Conditions studied

  • Dry Eye Syndromes

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must meet all the following criteria to be eligible:
  • Healthy, aged 18-50 (inclusive), all genders.
  • Signed pre-screening; comprehension of study and ability to complete it per protocol.
  • 19-27 kg/m² (inclusive); ≥45 kg for females, ≥50 kg for males.
  • Bilateral best-corrected visual acuity ≥4.7 (5m, 5-point logMAR).
  • No reported eye discomfort/abnormalities 1 month before randomization.
  • No history of dry eye disease, as assessed by the investigator.
  • No history of ocular inflammation (e.g., allergic conjunctivitis, uveitis) per investigator judgment.
  • Use effective during study and 30 days post-last dose:

Females: non-pregnant, non-lactating; premenopausal use approved methods, no egg donation.

Males with fertile partners: vasectomy (≥30 days, no viable sperm) or approved contraception, no sperm donation.

  • Non-smoker, remain smoke-free during study.
  • No excessive alcohol (>14 units/week) or illicit drug use history; abstain from both during study.

Exclusion criteria

Exclusion Criteria:

  • Subjects will be excluded if they meet any of the following:
  • History or current diseases/conditions (e.g., circulatory, endocrine disorders) that pose risks or interfere with the study, as judged by the investigator.
  • Blood donation or loss >300 mL within 56 days before randomization; no blood donation during the study.
  • Allergy to study medications (e.g., lifitegrast, ).
  • Prior participation in non - placebo lifitegrast clinical trials.
  • abnormal test results:

Vital signs: ear temp >37.7℃ or \<35.4℃; pulse >100 or \<60 bpm; systolic BP ≥150 or \<90 mmHg; diastolic BP ≥90 or \<50 mmHg.

: ≥450 ms (male), ≥460 ms (female). Lab tests: abnormal blood/urine, coagulation, infectious markers, drug/alcohol screenings.

Abnormal abdominal ultrasound or eye exams.

  • Intraocular/laser eye surgery within 12 months, other eye surgeries within 3 months before screening, or planned eye surgery during the study.
  • Use of ophthalmic drugs (incl. artificial tears), anticholinergics, oral/nasal within 1 month before screening or during the study.
  • Tobacco/nicotine use within 6 months before randomization.
  • Contact lens use within 1 month before randomization or during the study.
  • Prescription/OTC/herbal medications within 2 weeks or 5 half - lives (longer) before randomization or during the study.
  • Pregnancy, lactation, or positive pregnancy test at screening.
  • Participation in drug/device trials within 30 days or 5 half - lives (longer) before screening, or planned participation during the study affecting results.
  • Conditions increasing risks, affecting compliance, or deemed unsuitable by the investigator (e.g., needle phobia).
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Lifitegrast (T) on Day 1, then Xiidra® (R) on Day 8.

    Drug: Xiidra

  • Experimental
    Xiidra® (R) on Day 1, then Lifitegrast (T) on Day 8.

    Drug: Lifitegrast

Interventions

  • DrugXiidra

    Administered on Day 1 to subjects in Group B, and on Day 8 to subjects in Group A as part of a crossover study design.

  • Administered on Day 1 to subjects in Group A, and on Day 8 to subjects in Group B as part of a crossover study design.

06

What researchers measure

Primary outcomes

  1. Peak Plasma Concentration (Cmax)

    Evaluated in plasma and tears.

    Time frame: Day 1 & Day 8: Pre-dose, 10, 20, 30, 45 minutes, and 1 hour post-administration.

  2. Area Under the Plasma Concentration-Time Curve (AUC0-∞)

    Evaluated in plasma and tears.

    Time frame: Day 1 & Day 8: Pre-dose, 10, 20, 30, 45 minutes, and 1 hour post-administration.

  3. Area Under the Plasma Concentration-Time Curve (AUC0-t)

    Evaluated in plasma and tears.

    Time frame: Day 1 & Day 8: Pre-dose, 10, 20, 30, 45 minutes, and 1 hour post-administration.

  4. Time to Peak Plasma Concentration (Tmax)

    Assessment: Evaluated in plasma and tears.

    Time frame: Day 1 & Day 8: Pre-dose, 10, 20, 30, 45 minutes, and 1 hour post-administration.

  5. 5. Terminal Phase Half-Life (T1/2)

    Evaluated in plasma and tears

    Time frame: Day 1 & Day 8: Pre-dose, 10, 20, 30, 45 minutes, and 1 hour post-administration.

  6. Elimination Rate Constant (λz)

    Evaluated in plasma and tears.

    Time frame: Day 1 & Day 8: Pre-dose, 10, 20, 30, 45 minutes, and 1 hour post-administration.

  7. Percentage Extrapolated AUC (AUC_%Extrap)

    Evaluated in plasma and tears.

    Time frame: Day 1 & Day 8: Pre-dose, 10, 20, 30, 45 minutes, and 1 hour post-administration

07

Study locations

1 site
  • The First Affiliated Hospital of University of Science and Technology of China
    Hefei, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Dec 2022, 0 months.

Of 34 phase 1 interventional studies under Dry Eye Syndromes, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's 0 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2025
First posted
Jun 27, 2025
StartActual
Dec 6, 2022
Primary completionActual
Dec 19, 2022
CompletionActual
Apr 10, 2023
Last update
Jun 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07040826
Responsible party
Sponsor
First posted
Jun 27, 2025
Start date
Dec 6, 2022
Primary completion
Dec 19, 2022
Completion
Apr 10, 2023
Last update
Jun 27, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lifitegrast

Start the discussion